Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

ClinicalTrials.gov ID: NCT04451772

Public ClinicalTrials.gov record NCT04451772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)

Study identification

NCT ID
NCT04451772
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
185 participants

Conditions and interventions

Interventions

  • Elsubrutinib Drug
  • Placebo for Elsubrutinib Drug
  • Placebo for Upadacitinib Drug
  • Upadacitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2020
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Last update posted
Jan 13, 2025

2020 – 2024

United States locations

U.S. sites
21
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 227833 Phoenix Arizona 85032-9306
Wallace Rheumatic Studies Center, LLC /ID# 224374 Beverly Hills California 90211
Valerius Medical Group & Research Center /ID# 223922 Los Alamitos California 90720-5402
East Bay Rheumatology Medical /ID# 225493 San Leandro California 94578
University of Colorado Hospital /ID# 245087 Aurora Colorado 80045
Duplicate_Arthritis & Rheumatic Disease Specialties /ID# 227828 Aventura Florida 33180
Millennium Research /ID# 233192 Ormond Beach Florida 32174
IRIS Research and Development, LLC /ID# 227814 Plantation Florida 33324
Deerbrook Medical Associates /ID# 227330 Libertyville Illinois 60048
Qualmedica Research, LLC /ID# 227817 Evansville Indiana 47714-0805
The Center for Rheumatology and Bone Research /ID# 225479 Wheaton Maryland 20902
Beth Israel Deaconess Medical Center /ID# 222505 Boston Massachusetts 02215-5400
June DO, PC /ID# 221841 Lansing Michigan 48911
Duplicate_NYU Langone Health/NYU School of Medicine /ID# 245088 New York New York 10016-2772
STAT Research, Inc. /ID# 221840 Vandalia Ohio 45377-9464
Allegheny Health Network Research Institute /ID# 245086 Pittsburgh Pennsylvania 15224
Dr. Ramesh Gupta /ID# 225524 Memphis Tennessee 38119
Tekton Research, Inc. /ID# 224411 Austin Texas 78745
Accurate Clinical Management /ID# 225509 Houston Texas 77084
SW Rheumatology Res. LLC /ID# 225485 Mesquite Texas 75150
Carilion Clinic /ID# 227832 Roanoke Virginia 24016

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04451772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 13, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04451772 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →